StockTipsArenaBeta

SELL Biocon Ltd — Rajesh Satpute

SELLBiocon Ltd
Biocon share price target & all analyst calls
⏳ Pending entry — level not yet reached

byRajesh SatputeHorizon: 1–3 months9 Oct 2026via CNBC Awaaz.

Entry₹360Stated
Target₹335
Total upside +6.94%
Stop lossNot given
CMP₹349.413h ago
ActiveNA 3 mo left
Follow Rajesh Satpute for new calls(44% target hit, 18 closed calls)Get alertsWatch BIOCON for new buy/sell callsGet alertsSee 2 other Short-term calls on BIOCONSee 77 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 10 Oct, 5:33 am IST
3 supporting6 opposing
Supports the SELL call (3)

MACD below its signal line — bearish momentum

Technicals · macd·9 Oct · today

US Drug Tariff: 15 Pharma Stocks Likely to Be Impacted by Trump’s New Tariff Plan

NewsGoogle News·16 Sept · 3w ago

(opens in new tab)

2 advisors have active long-term SELL calls on this stock

Advisor consensus · adjacent horizon·15 Jul · 3mo ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the SELL call (6)

RSI at 25 — oversold territory

Technicals · rsi·9 Oct · today

Biocon Malaysia arm gets UK regulator approval for Semglee fill finish unit

NewsCnbc-Tv18·25 Sept · 2w ago

(opens in new tab)

Biocon's subsidiary received a positive opinion from EMA's CHMP for its Pertuzumab biosimilar (Pebrilzo) for HER2-positive breast cancer treatment. This is the first biosimilar to receive such recomme

BSE · Company Update·21 Sept · 3w ago

(opens in new tab)

Biocon's biosimilar Pertuzumab has received a positive recommendation from the EMA's CHMP under a new tailored clinical approach, marking a significant regulatory milestone.

NSE · Press Release·21 Sept · 3w ago

(opens in new tab)

2 other SEBI-registered advisors have active short-term BUY calls on this stock

Advisor consensus · same horizon·19 Sept · 3w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Rajesh Satpute

Every call and its outcome